Overview
This 11-question pulse survey of 74 dermatologists practicing throughout the US and Europe asks respondents their thoughts on results from the ECLIPSE study, which was designed to compare the efficacy and safety of Tremfya (guselkumab; Johnson & Johnson) and Cosentyx (secukinumab; Novartis) over one year of treatment for moderate-to-severe plaque psoriasis, as well as to estimate current and future prescribing trends for the treatment of psoriasis.
This 11-question pulse survey of 74 dermatologists practicing throughout the US and Europe asks respondents their thoughts on results from the ECLIPSE study, which was designed to compare the efficacy and safety of Tremfya (guselkumab; Johnson & Johnson) and Cosentyx (secukinumab; Novartis) over one year of treatment for moderate-to-severe plaque psoriasis, as well as to estimate current and future prescribing trends for the treatment of psoriasis.
